Nail dystrophy successfully treated with dupilumab in pediatric atopic dermatitis: case series and literature review.

Atopic dermatitis (AD) is a common chronic, recurrent inflammatory disease, yet its accompanying nail abnormalities have long received insufficient attention. The clinical characteristics, underlying mechanisms, and assessment systems for nail dystrophy in AD remain unclear. AD-associated nail dystrophy can manifest in various forms, including Beau's lines, nail pitting, koilongchia, trachyonychia, leukonychia, brachyonychia, melanoychia, onychomadesis, onychoschizia, onycholysis, and paronychia. Current treatments face limitations such as slow onset of action and uncertain efficacy with traditional therapies, particularly with limited drug options for the pediatric populations. With the deepening of research into the Th2 inflammatory pathway, biologics such as dupilumab have shown therapeutic potential. Through retrospective analysis, this paper presents the effectiveness and safety of dupilumab in five pediatric AD patients with nail dystrophy under 12 years old. After at least 12 weeks of treatment, their skin lesions and nail dystrophy both showed marked improvement. Additionally, we reviewed four reported cases in the literature of adult AD patients with nail dystrophy who experienced significant improvement in nail changes after dupilumab treatment. These results suggest that dupilumab may be an effective treatment for nail dystrophy in AD. This case series provides the first evidence demonstrating the significant efficacy of dupilumab for nail dystrophy in pediatric AD patients. However, further large-scale prospective studies are still needed to better guide clinical practice.